United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - arimidex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. arimidex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. arimidex is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to arimidex. hypersensitivity arimidex is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. observed reactions include anaphylaxis, angioedema, and urticaria [see adverse reactions (6.2)] . risk summary based on findings from animal studies and its mechanism of action, arimidex may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no studies of a

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: macrogol 300; titanium dioxide; hypromellose; povidone; sodium starch glycollate; magnesium stearate; lactose monohydrate - early breast cancer: adjuvant treatment of early breast cancer in post-menopausal women with oestrogen/progesterone receptor positive disease. advanced breast cancer: first line treatment of advanced breast cancer in post-menopausal women with oestrogen/progesterone receptor positive disease. treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. patients with oestrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to arimidex,

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - arimidex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. arimidex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. arimidex is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to arimidex. arimidex may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. arimidex is contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using arimidex. if arimidex is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - anastrozole -

Israel - English - Ministry of Health

taro international ltd, israel - anastrozole - film coated tablets - anastrozole 1.0 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - anastrozole - film-coated tablet - 1 milligram(s) - aromatase inhibitors; anastrozole

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - anastrozole - oral tablet - 1mg

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca ab - anastrozole - film-coated tablet - 1 milligram(s) - aromatase inhibitors; anastrozole

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - anastrozole - tablet, film coated - 1 mg - anastrozole 1 mg

Malta - English - Medicines Authority

astrazeneca uk limited - anastrozole - film-coated tablet - anastrozole 1 mg - endocrine therapy